Escitalopram is an antidepressant drug known as a selective serotonin reuptake inhibitor. Among the antidepressants, the most prominent group in terms of their antimicrobial effects are Serotonin Reuptake Inhibitors and tricyclic antidepressants. Many studies have shown that antidepressant drugs have antibacterial activity. Increasing resistance problems have led researchers to investigate the effectiveness of agents without antibacterial activity in primary care. In this study, the antituberculosis effect of escitalopram and its effectiveness on primary antituberculosis drugs isoniazid and rifampicin were tested on Mycobacterium tuberculosis ATCC strains and 18 clinical isolates (15 multidrug-resistant and three susceptible). In this study, the active ingredient escitalopram alone or in combination with antibiotics did not exhibit any antituberculosis effect. The minimum inhibitory concentration was>256 μg/ml for all ATCC and clinical isolates studied. In addition, no antagonistic or synergistic effects were found in our study to determine the effectiveness of escitalopram on isoniazid and rifampicin, which are primary antituberculosis drugs.